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The accuracy of sentinel lymph-node biopsy in breast
cancer after previous excisional biopsy
Antonio Marrazzo1, 2, Pietra Taormina2, Emilia Marrazzo1, Attilio Ignazio Lo Monte1,
Giuseppe Buscemi1
1 Dipartimento di Discipline Chirurgiche, Oncologiche e Stomatologiche, Facoltà di Medicina e Chirurgia, Università degli
Studi di Palermo, Palermo, Italy; 2Breast Unit Casa di Cura Macchiarella, Palermo, Italy
Summary. Aim: Sentinel node biopsy (SLNB) is considered to be the standard of care for staging the axilla
in clinically node-negative women with breast cancer. A previous breast excisional biopsy has been consid-
ered a contraindication to the use of SLNB.We examined the success rate of SLN localization and then the
evaluation of the incidence of axillary relapse in patients with breast cancer undergoing excisional biopsy.
Patients and Methods: 858 patients with breast carcinoma underwent a SLNB and only positive sentinel
nodes were submitted to axillary dissection; 82 patients had undergone an excisional biopsy before. Results:
The sentinel node was identified in 100% of cases, it was negative in 74.4% and positive in 23.1%. Complete
axillary dissection was performed in all positive cases, and in 74% of cases no other positive nodes were
found. The follow-up median was 63.5 months and no axillary recurrence was observed. Conclusions: SLNB
accuracy in breast cancer patients who have previously undergone excisional biopsy is comparable with that
in patients undergoing no excisional biopsy, so that it may be considered a standard procedure.
Key words: breast cancer, excisional biopsy, sentinel lymph-node biopsy, accuracy
«L’ACCURATEZZA DEL LINFONODO SENTINELLA DOPO BIOPSIA ESCISSIONALE DEL CARCINOMA DELLA
MAMMELLA»
Riassunto. Scopo: La biopsia del linfonodo sentinella (BLS) nel carcinoma della mammella con linfonodi
ascellari clinicamente negativi è considerato la migliore scelta per stadiare il cavo ascellare. Inizialmente una
precedente biopsia escissionale del carcinoma era considerata una controindicazione. Esaminiamo il tasso di
successo della BLS e la incidenza della recidiva a livello ascellare in pazienti con carcinoma della mammella
precedentemente sottoposti a biopsia escissionale del tumore. Pazienti e metodi: 858 pazienti con carcinoma
della mammella sono stati sottoposti a BLS e i pazienti con linfonodi sentinella metastatici a svuotamento
del cavo ascellare; 82 pazienti erano stati sottoposti precedentemente a biopsia escissionale del tumore. Ri-
sultati: Il linfonodo sentinella è stato identificato nel 100% dei casi, è risultato indenne nel 74,4% e meta-
statico nel 23,1%. La dissezione del cavo ascellare è stata effettuata in tutti i casi con linfonodi sentinella me-
tastatici e nel 74% dei casi non si sono ritrovati altri linfonodi ascellari metastatici. Il follow-up mediano è
stato di 63,5 mesi e non si sono osservate recidive ascellari.Conclusioni: L’accuratezza del BLS in pazienti con
carcinoma della mammella sottoposte precedentemente a biopsia escissionale è uguale a quella dei pazienti
non sottoposti a biopsia.
Parole chiave: carcinoma della mammilla, biopsia escissionale, linfonodo sentinella, accuratezza
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Introduction
Nowadays the sentinel lymph-node biopsy
(SLNB) is the standard of care in women who have
been confirmed by ultrasound as clinically node nega-
tive.
Particularly, if the SLNB is not metastatic, the
patient will not need to undergo an axillary lymph-
node dissection (ALND). We have the results of
several trials and meta-analysis, in which the total
survival, the disease-free survival and regional control
were statistically equivalent between patients who
were randomized to completion axillary dissection or
no completion axillary dissection after a negative
SLNB (1-3).
SLNB represents a significant advance in the
staging of breast cancer, since it avoids the morbidity
of axillary dissection in node-negative women. In fact
SLNB is associated with reduced arm morbidity,
moderated or severe lymphedema, and better quality
of life than standard axillary treatment (4).
Initially to ensure and maintain the high accuracy
and low false-negative rate of the SLNB procedure,
several selection criteria and related contraindications
for the procedure have been reported, the latter
including a previous excisional biopsy. The reason for
the contraindications for the previous excisional
biopsy was the possibility of an altered anatomy of the
lymphatic channels of the breast, thereby hindering
the clear identification of the sentinel node.
This study is a retrospective analysis of the
success rate, accuracy, and negative predictive value of
SLN localization and also an evaluation of the inci-
dence of axillary relapse in patients with breast cancer
undergoing excisional biopsy.
Materials and methods
Between February 1999 and December 2008, 858
patients with breast carcinoma underwent a SLNB
and only those who were sentinel node-positive were
submitted for axillary dissection. Out of 858 patients,
82 patients had undergone an excisional biopsy before
and 42 patients (51%) had been treated in other
centres before coming to our institute. Out of these 82
patients, 17 showed SLN localization by both radio-
colloid and blue dye, and 65 by radio- colloid only. All
patients also received partial or total resection of the
breast to obtain disease-free surgical margins. A
detailed report of both methods used to identify the
SLN is provided in a previous trial carried out by the
authors (5).
Complete axillary dissection was performed
when the sentinel nodes contained metastases.
Before 2003, histological examination of the
sentinel node was performed on a few sections of the
specimen, such as the lymph nodes of a typical axillary
dissection. Starting from March 2003, the number of
sections was increased so that a complete examination
of the whole sentinel node to detect micrometastases
was possible.
Here is described the technique used in our insti-
tution. First of all, the SLN is sliced at 2 mm intervals
perpendicular to the long axis. One routine Haema-
toxylin-Eosin (H&E) stained section is examined; if
negative, serial level slices are performed through each
block (two sections for each level, with a spacing of
50 µ between the following levels). One segment for
each level is stained with H&E while the other under-
goes an additional immuno-histochemical analysis
with keratins to compare clusters of histologically
suspected cells. This approach offers a good sensitivity
in order to detect any micrometastases and isolated
tumoral cells, and with reasonable costs. All patients
underwent a follow-up every 4-6 months, depending
on the axillary status, during the first 5 years after
surgery. Bilateral mammograms were annually
repeated; breast and axillary ultrasound were repeated
every 6 months. The staging of the disease was imme-
diately performed before the surgery with bone
scintigraphy; liver ultrasound X-rays of the chest had
been pre-operatively performed.
We usually repeat the staging at time intervals
that depend on the initial extension of the disease and
the clinical observation during the follow-up.
Results
Between February 1999 and December 2008, 82
patients with invasive breast cancer, already treated
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with excisional biopsy and clinically negative, were
included in this study. Their characteristics are shown
in Table 1. The median age at the time of entering the
study was 49 (range 24-82). The average size of the
primary carcinoma was 1.2 cm. In 11 patients (13.4%)
it was under 0.5 cm, in 19 patients (23.2%) it was
between 0.5-1 cm, in 26 patients (31.7%) it was
between 1-1.5 cm, in 20 patients (24.4%) it was
between 1.5-2 cm, and in 6 patients it was between
2-3 cm. The most common histological type was
ductal carcinoma, in 60 patients (76.1%). Lobular
carcinomas were observed in 10 patients (12.1%),
mixed ductal and lobular carcinomas in 1 patient
(1.2%), while 11 patients (13.3%) showed different
types of carcinoma, mainly well-differentiated forms
(cribriform, tubular, mucinous and papillary).
Most patients (75, 93.5%) were treated with
breast conservative surgery followed by external-beam
radiotherapy on the whole breast through two tangen-
tial fields (50 plus 10 Gy as a boost to the tumour bed)
with a linear accelerator, while 7 patients (8.5%) were
treated with total mastectomy. In 28 cases (34%) we
found residual carcinoma, in 16 of them (19.5%) it
was in situ and in the others (14.6%) it was invasive.
The sentinel node was identified in 100% of cases and
was negative in 61 patients (74.4%), while it was posi-
tive in 19 ones (23.1%); while in 2 patients only
isolated tumoral cells were present (Table 2).
Complete axillary dissection was performed in all 19
patients with sentinel node positive and in 14 cases
(74%) no other positive nodes were found (Table 3).
None of the patients within this group experi-
enced axillary recurrence at follow-up (median 63.5
months and range 37 to 146 months).
Discussion
A previous breast excisional biopsy has been
considered a contraindication to the use of SLNB as it
was commonly supposed that the excisional biopsy
resulted in subsequent disruption of the breast
lymphatic drainage. Some authors have suggested that
altered lymphatic drainage decreases the likelihood of
successful lymphatic mapping, and indeed have
suggested that any nodes removed after an excisional
biopsy may not actually represent an accurate reflec-
tion of lymphatic drainage from the site of primary
tumour (6-11).
In recent years, due to several studies on the
sentinel node, we have come to better understand the
anatomy involved in the lymphatic drainage of the
breast. In the past we believed that different sentinel
Table 1.
Characteristics N. %
Tumour grade
G1 26 31.7
G2 20 24.3
G3 14 17.0
Unknown 22 26.8
Histological type
Ductal 60 73.1
Lobular 10 12.1
Ductal+lobular 1 1.2
Tubular 2 2.4
Papillary 6 7.3
Other 3 3.6
Proliferative fraction (Ki67)
<20% 38 46.3
>20% 26 40.8
Unknown 18 21.9
ER
Absent 17 20.7
Present 53 64.6
Unknown 12 14.6
PgR
Absent 18 21.9
Present 52 63.4
Unknown 12 14.6
HER2/neu overexpression
0/1+ 51 62.2
2+ 12 14.6
3+ 7 8.5
Unknown 12 14.6
Type of surgery
Total mastectomy 7 8.5
Breast conserving surgery 75 91.5
Tumour size
<0.5 cm 11 13.41
0.5-1 cm 19 23.17
1-1.5 cm 26 31.70
1.5–2 cm 20 24.39
2-3 cm 6 7.31
pT
pT1a 11 13.41
pT1b 19 23.17
pT1c 46 56.09
pT2 6 7.31
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nodes existed in relationship to the different quad-
rants, while studies on multicentric cancer had shown
that there is only one sentinel node. Multiple
lymphatic trunks might drain to different sentinel
lymph node(s) and may be overlooked. However, with
the use of lymphatic mapping and the increased expe-
rience in SLNB, there is now increasing evidence-
based support of the theory that the lymphatics of the
mammary gland drain through a few common
afferent lymphatic trunks to specific axillary sentinel
lymph nodes, regardless of the tumour location (12,
13). Ferrari et al. demonstrated that intradermal
radioisotope injections in two different quadrants of
the breast give the same SLN visualization in most
cases (14).
Kim et al. reported five patients with multicentric
breast cancer who had undergone a sentinel node
mapping and a biopsy procedure. Clinically each
patient showed carcinoma in two different quadrants
of the breast. One tumor was mapped with tech-
netium-labeled sulfur colloid and the other was
mapped with isosulfan blue dye. In each case at least
one both hot and blue node was identified in the axilla
(15).
The possibility of a high rate of false negative
results in patients who had previously undergone an
excisional biopsy for cancer was refuted by studies in
which the sentinel node was isolated and simultane-
ously ALND was performed: in Maza et al. the
sentinel node was identified in 100% of cases and it
was positive in 22.2%, the false -negative rate was 0%
(16). Wong et al. reported a rate of identification of
92.5% and a false-negative rate of 8%; the sentinel
node was metastatic in 33.9% (17); Heuts et al.
reported a rate of identification of 98% and a false-
negative rate of 0% (18); Coskun et al. reported a rate
of identification of 98% and a false-negative rate of
6.4% (19); Blanco et al. reported a rate of identifica-
tion of 92.1% (20).
In our study the sentinel node was identified in
100% of cases, was positive in 23% and was the only
positive node in 73.6% of cases with positive axillary
node. In the entire population up to 2008 the sentinel
node was positive in the 38% of cases and was the only
positive node in 58.2% of cases.
The high percentage of negative sentinel nodes is
related to the fact that the case-sample that previously
underwent excision biopsy contained a higher propor-
tion of small-sized tumours with respect to the total
study population, indeed pT1a is 13.4% against 4.2%,
pT1b is 23.1% against 13.7%; meanwhile the presence
of cancers with a diameter larger than 2 cm is 7.3%
against 25.8%. No lymph node recurrence was
observed during a median follow-up time of 63.5
months.
Van der Ploeg and colleagues reported an identi-
fication rate of 96.5% in patients who underwent the
excisional biopsy, and no lymph node recurrence was
detected during follow-up (median 39 months) (21).
Ohtake et al. compared sentinel lymphoscinti-
grams in breast cancer patients who had previously
undergone excisional biopsy with sentinel lympho-
scintigrams in patients undergoing no excisional
biopsy, and reported a rate of identification respec-
tively of 98% and of 99% (22).
Luini et al. reported an identification rate of 99%,
in the 29.6% of cases the SLN was positive, and was
the only positive node in 61.5%; an axillary relapse in
0.8% of cases was observed (23).
The possibility that a breast carcinoma might be
removed as a result of diagnostic error depends on the
experience of the centre, but is higher in small-size
tumours, in well-differentiated tumours and in young
patients. In such cases the probability of negative axil-
lary lymph nodes is high and for this reason avoiding
axillary dissection is important in order to improve
quality of life.
Table 2. Characteristics of sentinel node
N. %
N 0 61 74.39
N+ 19 23.17
Isolated tumoral cells 2 2.43
Table 3. Characteristics of axillary dissection in sentinel node
positive
N. %
N 0 14 73.68
N+<3 1 5.26
N+>3 4 21.05
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Conclusion
Our results and literature review confirm that, in
patients who have previously undergone excisional
biopsy, sentinel node biopsy may be used to identify
those patients with a negative sentinel node, that are a
higher percentage than the total case study, thus
avoiding a complete axillary dissection.
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